RT Journal
A1 Jindeel A
T1 ARe we ignoring the elephant in the room?
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2007
FD November 12
VO 167
IS 20
SP 2263
OP 2264
DO 10.1001/archinte.167.20.2263
UL http://dx.doi.org/10.1001/archinte.167.20.2263
AB 
Cook et al1 reported no association between migraine and coronary heart disease (CHD) after a mean of 12 years of follow-up in the Physicians' Health Study (PHS). This study included information through March 2000. Kurth et al2 extended the follow-up period of the PHS participants to February 2005. They concluded that “migraine was associated with increased risk of major CVD [cardiovascular disease]”2(p795) and that “[t]he associations between migraine and major CVD, ischemic stroke, and MI [myocardial infarction] were not significantly modified by smoking and hypertension status or by randomized aspirin assignment.”2(p797) The authors “had no information about the use of migraine-specific drugs (ie, triptans and ergot alkaloids).”2(p800) However, in a study by the same authors regarding the Women Health Study “women were asked on the 48-month questionnaire to provide information regarding medication use during the previous 2 weeks. The frequency of migraine-specific drug use among women who reported active migraine at baseline was 5.3%.”3(p290) So what did these patients use to treat their migraine?